Navigation Links
OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
Date:6/24/2009

lumbia. The revised trial will be a randomized, controlled, international study in 800 men with metastatic CRPC who are in need of first-line chemotherapy. Patients will be randomized to receive treatment with either OGX-011 and docetaxel/prednisone or docetaxel/prednisone alone. The primary endpoint of the study will be overall survival. It is expected that approximately 80 sites, primarily from United States and Canada, will participate in this study.

The planned initiation of this Phase 3 trial evaluating survival is supported by Phase 2 data from patients receiving OGX-011 plus docetaxel as first-line chemotherapy presented at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) and reported on May 30th of this year. Analyses indicated the median overall survival in patients with advanced metastatic prostate cancer who were treated with OGX-011 plus docetaxel in a randomized Phase 2 trial was 23.8 months compared to 16.9 months for patients treated with docetaxel alone -- a 6.9 month observed survival advantage for the OGX-011 arm. Furthermore, the unadjusted hazard ratio (HR), a measure used to compare the death rates between treatment groups, was 0.61, representing a 39% lower rate of death for patients treated with OGX-011.

About OGX-011

OGX-011 is designed to inhibit the production of clusterin, a protein that is associated with cancer treatment resistance, and has completed Phase 2 clinical trials in prostate, lung and breast cancer.

Based on clinical results to date, OncoGenex intends to conduct two Phase 3 registration trials with OGX-011 in metastatic castrate resistant prostate cancer, subject to the receipt of additional funding. The U.S. Food & Drug Administration (FDA) has now agreed on the design of both Phase 3 registration trials, via the Special Protocol Assessment (SPA) process, of OGX-011 in combination with chemotherapy. One trial design investigates overall sur
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
2. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
3. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
4. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
5. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
6. OncoGenex Reports First Quarter Financial Results
7. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
8. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
9. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
10. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
11. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...  Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ... Trial Application (CTA) with the United Kingdom,s ... regulatory approval to initiate clinical trials for the continued ... Contingent on the Company receiving CTA regulatory approval, the ... assess the safety, tolerability and dose escalation of Anatabine ...
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ - RepliCel Life ... regenerative medicine company focused on the development of autologous ... out of the University of Calgary in conjunction with ... Carolina, which further validates the company,s ongoing clinical research ... effects of pattern baldness. The paper entitled ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 ... peer-reviewed publication of original research, reviews and editorials ... and clinical practice, today published a provocative article ... the development, progression and potential treatment of prostate ... endocrinology research and proposes the possibility that there ...
(Date:12/19/2014)... Lawrence, MA (PRWEB) December 19, 2014 ... flow MRLAFMQ test for the Detection of Aflatoxin M1 ... test to receive independent third party validation. The peer ... Science Unit of the Institute for Agricultural and Fisheries ... Francis Group. , Aflatoxin B1, the most toxic ...
Breaking Biology Technology:Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2
... All Conditions to the Tender Offer Have Been Satisfied, ... and,Investments Ltd. (TASE: CII) announced today that all of ... to purchase,up to 2,338,686 ordinary shares of Fundtech Ltd. ... to the seller in cash, less any required,withholding taxes ...
... and employees in Massachusetts, encompassing over 250,000 square feet for ... ... CANTON, Mass., April 3, 2008 Joined by local officials,and Organogenesis, ... company, which was once,planning to move its operations outside of the ...
... DNDN ) today announced that it has entered into ... million shares of its,common stock and warrants to purchase ... gross proceeds of approximately $47 million, before,deducting placement agent ... The investor has agreed to purchase the,shares of common ...
Cached Biology Technology:Clal Industries Commences Additional Offer Period for Fundtech Tender Offer 2Clal Industries Commences Additional Offer Period for Fundtech Tender Offer 3Governor Patrick Announces Life Sciences Initiative Victory With Organogenesis' New Headquarters 2Governor Patrick Announces Life Sciences Initiative Victory With Organogenesis' New Headquarters 3Governor Patrick Announces Life Sciences Initiative Victory With Organogenesis' New Headquarters 4Dendreon Announces $47 Million Registered Direct Offering 2Dendreon Announces $47 Million Registered Direct Offering 3
(Date:12/22/2014)... , Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... entertainer and security consultant, Apollo Robbins for ... smart wallet.  Apollo Robbins ... 7 th , 2015, demonstrating some of his famous ...
(Date:12/19/2014)... 18, 2014 Research and Markets ( ... "Micro Market Monitor: North America Perimeter Security Systems Market" ... http://photos.prnewswire.com/prnh/20130307/600769 The North American perimeter ... of 3.6% from 2014 to 2019. Although the U.S. ... Canada is expected to grow at ...
(Date:12/17/2014)... 15, 2014 The Defense Logistics Agency ... to detect and prevent counterfeit microcircuits from entering ... agency started performing an in-house microcircuit anti-counterfeit initiative ... authenticity of purchased microcircuits while increasing their reliability ... measures will be conducted at DLA,s Electronics Product ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3
... Some of the most commonly prescribed drugs for the ... to relax blood vessels and decrease the heart,s workload. The ... pathways, but according to a new study led by scientists ... may help the failing heart by counteracting the effects of ...
... at San Antonio Chemistry Professor Carlos Garcia, UTSA Physics ... of Santa Clara, Calif. have been awarded more than ... of a "lab-on-a-robot" (LOAR). The Rover-like prototype will be ... Utilizing wireless technology, the current LOAR is able to ...
... pigeons, like other birds, are extraordinary navigators, but how they manage ... To navigate, birds require a ,map, (to tell them home is ... is), with the sun and the Earth,s magnetic field being the ... the information pigeons use as a map is in fact available ...
Cached Biology News:Temple researchers uncover clues to how existing heart drugs work 2UTSA chemist awarded $300,000 in NASA funding to build 'lab on a robot' prototype 2How pigeons may smell their way home 2How pigeons may smell their way home 3